A Phase 4 interventional study of Gandouling in Wilson's Disease, sponsored by Jun Li. Recruiting at 1 site in China. Open to participants aged 15 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-02-09.
Sponsored by Jun Li · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Hepatolenticular Degeneration with a site in China — 10 open to participants now, 11 under way, 1 of them phase 3. Hepatolenticular Degeneration · China.
Among the 15 studies in Hepatolenticular Degeneration with a site in China, this one is the only one that started in 2023, is the only one in phase 4, reaches primary completion later than 1 of the 10 other live ones, and was the 7th registered.
80 studies on the registry are indexed under Hepatolenticular Degeneration; 31 are open to participants now.
Browse Hepatolenticular Degeneration studies →10 of the 15 studies in Hepatolenticular Degeneration with a site in China are open now. Recruiting first, the newest first:
Orphalan · Sites in China, United States, Pakistan and 1 more country
Ages 8+
GeneCradle Inc · Sites in China
Ages 18+
DSciLab Co., Ltd. · Sites in China
Ages 18+
Chaohui Yu · Sites in China
Ages 10–60
Wan-Jin Chen · Sites in China
Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 22 Hepatolenticular Degeneration studies recruiting now, 17 (77%) set no upper age limit and 4 (18%) stop at 75 or younger; 14 take children under 18; 3 take healthy volunteers.
This study: 15 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 2 · Phase 3 1 · Phase 4 1
First in 2004; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 240 is above the median of 30 across 44 interventional studies indexed under Hepatolenticular Degeneration.
Median enrollment 18 across the 9 interventional studies, 600 across the 6 observational. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 15 have an industry lead sponsor. The 10 most frequent:
Jun Li is the lead sponsor of 10 studies on the registry; 1 is open to participants now.
Jun Li has 1 study filed under Hepatolenticular Degeneration — fewer than ten, so there is no comparison to draw.
1 of the studies in Hepatolenticular Degeneration with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06650319Chaohui YuA Clinical Study to Evaluate the Safety and Efficacy of LY-M003 Injection in Patients With Wilson Disease | 2026-12-30 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies in Hepatolenticular Degeneration with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the efficacy and safety of gandouling tablet in the treatment of clinical symptoms of Wilson's diasease.
To evaluate the efficacy and safety of gandouling tablet in the treatment of clinical symptoms of Wilson's diasease.Test various indicatorsbefore test, 4 weeks, 12 weeks and 24 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Gandouling
Drug: Gandouling
Zinc gluconate
Drug: Gandouling
The experimental group was given gandouling tablet + zinc gluconate simulant; The course of treatment was 24 weeks.
Also known as: zinc gluconate
Unified Wilson's Disease Rating Scale(UWDRS)
Unified Wilson's Disease Rating Scale(UWDRS),the minimum is 0, and the maximum value is 320. Higher scores mean a worse outcome.
Time frame: Baseline, before the study
Unified Wilson's Disease Rating Scale(UWDRS)
Unified Wilson's Disease Rating Scale(UWDRS). Higher scores mean a worse outcome.
Time frame: 4 weeks
Unified Wilson's Disease Rating Scale(UWDRS)
Unified Wilson's Disease Rating Scale(UWDRS).Higher scores mean a worse outcome.
Time frame: 12 weeks
Unified Wilson's Disease Rating Scale(UWDRS)
Unified Wilson's Disease Rating Scale(UWDRS).Higher scores mean a worse outcome.
Time frame: 24 weeks
24-hour urinary copper
24-hour urinary copper.Higher scores mean a worse outcome.
Time frame: Baseline, before the study
24-hour urinary copper
24-hour urinary copper.Higher scores mean a worse outcome.
Time frame: 4 weeks
24-hour urinary copper
24-hour urinary copper.Higher scores mean a worse outcome.
Time frame: 12 weeks
24-hour urinary copper
24-hour urinary copper.Higher scores mean a worse outcome.
Time frame: 24 weeks
non-ceruloplasmin bound copper (NCC)
non-ceruloplasmin bound copper (NCC).Higher scores mean a worse outcome.
Time frame: Baseline, before the study
non-ceruloplasmin bound copper (NCC)
non-ceruloplasmin bound copper (NCC).Higher scores mean a worse outcome.
Time frame: 4 weeks
non-ceruloplasmin bound copper (NCC)
non-ceruloplasmin bound copper (NCC).Higher scores mean a worse outcome.
Time frame: 12 weeks
non-ceruloplasmin bound copper (NCC)
non-ceruloplasmin bound copper (NCC).Higher scores mean a worse outcome.
Time frame: 24 weeks
Global Assessment Scale (GAS)
Global Assessment Scale (GAS).Higher scores mean a worse outcome.
Time frame: Baseline, before the study
Global Assessment Scale (GAS)
Global Assessment Scale (GAS).Higher scores mean a worse outcome.
Time frame: 4 weeks
Global Assessment Scale (GAS)
Global Assessment Scale (GAS).Higher scores mean a worse outcome.
Time frame: 12 weeks
Global Assessment Scale (GAS)
Global Assessment Scale (GAS).Higher scores mean a worse outcome.
Time frame: 24 weeks
Short Form-36 Questionnaire (SF-36)
Short Form-36 Questionnaire (SF-36).Higher scores mean a worse outcome.
Time frame: Baseline, before the study
Short Form-36 Questionnaire (SF-36)
Short Form-36 Questionnaire (SF-36).Higher scores mean a worse outcome.
Time frame: 4 weeks
Short Form-36 Questionnaire (SF-36)
Short Form-36 Questionnaire (SF-36).Higher scores mean a worse outcome.
Time frame: 12 weeks
Short Form-36 Questionnaire (SF-36)
Short Form-36 Questionnaire (SF-36).Higher scores mean a worse outcome.
Time frame: 24 weeks
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2023 to primary completion in Mar 2023, 2 months.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gluconic acid
Hepatolenticular Degeneration →
Jun Li